Novo Nordisk $NVO climbs after raising its outlook! About time...
Novo Nordisk really needed this quarter after two years of disappointment. The company beat expectations on almost all major metrics and raised its full-year outlook for the third time this year. As a result, shares are up 6%.
Wegovy in tablet form is not just an addition to injections; it is starting to become a genuine growth driver. Tablet sales are rising faster and can already offset weaker performance by the injectable version in the US and pricing pressure on older products.
This is a major shift from a year ago, when the company was struggling to meet its outlook and losing market share to Eli Lilly $LLY.
At the same time, I’m not getting carried away with optimism, even though I’m still holding the shares. 2026 is still a year of resetting for Novo, and even after raising its outlook, we’re talking more about stagnation than a return to any kind of exceptional growth. Lilly is still rapidly gaining new patients with its Foundayo pill, so the competitive battle over obesity treatment pills is in full swing.
How are you positioned in $NVO?
